Ancora Advisors LLC Purchases 53,750 Shares of Omeros Corporation $OMER

Ancora Advisors LLC raised its stake in Omeros Corporation (NASDAQ:OMER - Free Report) by 46.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 168,750 shares of the biopharmaceutical company's stock after purchasing an additional 53,750 shares during the quarter. Ancora Advisors LLC owned 0.23% of Omeros worth $1,605,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. UBS Group AG lifted its holdings in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock worth $38,180,000 after acquiring an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP increased its position in Omeros by 85.2% during the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock worth $1,897,000 after purchasing an additional 82,646 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at $57,484,000. Bank of America Corp DE grew its stake in shares of Omeros by 57.8% during the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company's stock valued at $2,163,000 after buying an additional 74,997 shares during the period. Finally, Corient Private Wealth LP acquired a new stake in shares of Omeros during the 2nd quarter worth $6,274,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Peter Cancelmo sold 25,000 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. The trade was a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 105,906 shares of company stock worth $1,989,705 over the last three months. Corporate insiders own 10.50% of the company's stock.

Omeros Price Performance

Shares of NASDAQ OMER traded down $0.05 during mid-day trading on Tuesday, reaching $19.38. 392,591 shares of the company traded hands, compared to its average volume of 1,687,282. Omeros Corporation has a fifty-two week low of $4.05 and a fifty-two week high of $21.24. The firm has a market cap of $1.40 billion, a PE ratio of 15.14 and a beta of 2.60. The stock has a fifty day simple moving average of $16.40 and a 200-day simple moving average of $13.11.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Cantor Fitzgerald raised Omeros from a "neutral" rating to an "overweight" rating and set a $22.00 price target on the stock in a report on Tuesday, September 22nd. Wall Street Zen upgraded Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Weiss Ratings cut Omeros from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, September 22nd. Finally, Zacks Research lowered shares of Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.00.

Omeros Company Profile

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.